 Humanigen Inc NASDAQ: HGEN has reported topline data from Phase 3 study evaluating its lead drug candidate, lenzilumab, in patients hospitalized with COVID-19. The 520-patient study demonstrated that lenzilumab significantly improved patient outcomes. 